1. Introduction {#sec1}
===============

We report a case of anterior segment ischaemia following treatment with multiple intra-arterial chemotherapy (IAC) infusions.

2. Case report {#sec2}
==============

A 5 month old white female presented with right leukocoria. She had no significant family history. She was diagnosed with bilateral retinoblastomas, Group E (right eye) and group B (left eye) according to International Intraocular Retinoblastoma Classification1, H1cT3c (Right Eye) H1cT1b (left eye)[@bib1] Genetic analysis revealed a heterozygous *RB1* exon 17 mutation (c.1630delA) The right Group E eye[@bib2] was enucleated at presentation. Her left eye had five extra-foveal tumours for which she received six cycles of systemic chemotherapy with vincristine, etoposide and carboplatin.

Tumor \#1 was close to the optic nerve and relapsed repeatedly despite judicious transpupillary therapy away from the nerve ([Fig. 1](#fig1){ref-type="fig"}). It was treated a total of 12 infusions of IAC (4 cycles of 3 injections each at 3 weeks apart). For her first round of treatment, she received 2 doses each of 3mg melphalan and 0.3mg Topotecan. The final dose was increased to 4mg and topotecan 0.3mg as we use age appropriate doses[@bib3]^,^[@bib4] and she had turned 12 months. This was effective for 2 years and 5 months and there were no complications from the IAC. Tumor\#1 relapsed again and this time 5mg melphalan and 1 mg topotecan was used for the 3 injections of the 2nd cycle. A slight ptosis and supratrochlear rash followed but no other complications ensued. There was a complete response following the second cycle. After 4 months, Tumor \#1 relapsed again and as she was 4 years of age, the dose was increased to melphalan 7.5mg and topotecan 1.5mg for her 3rd cycle and she developed lid swelling. Our practice is to give steroid drops for 3 weeks and oral steroids for 5 days tds (100 μg/kg). After the swelling she developed a third and sixth nerve palsy with an increase in the ptosis. The sixth nerve palsy was severe causing a −7 limitation of movement (severe restriction past the midline). Again, a complete response was achieved. There was no neutropenia after chemotherapy. After 5 months, yet again Tumor \#1 relapsed and as the maximum dose of melphalan had already been given (for our unit), we opted for carboplatin 30mg and topotecan 1.5mg. After the twelfth IAC, she developed an area of conjunctival and scleral ischaemia between 12 and 3 o\'clock meridians in her left eye ([Fig. 2](#fig2){ref-type="fig"}). Fluorescein demonstrated conjunctival ischaemia in this region ([Fig. 3](#fig3){ref-type="fig"}). There was no corresponding corneal epithelial abnormality and at 14 months following the onset of this sign (5 years after her initial diagnosis), she is pain free with visual acuity of LogMAR 0.34 with an adjusted head posture to compensate for her ptosis and third and sixth cranial nerve palsies. Tumor \#1 has regressed without further relapse. There was no corresponding area of choroidal ischaemia on fluorescein angiography. There has been no scleromalacia or anterior staphyloma. The sixth nerve palsy has improved over 24 months from −7 to −4.5 limitation but the upward limitation remains at −3.5 and downward limitation has improved from −3.5 to −2.5. There is restriction in all directions when forced duction tests were performed and the eye is enophthalmic. The ptosis has slightly improved but remains after 24 months. She had a dominant accessory supply from the middle meningeal artery and this was used for the first 9 treatments. Unfortunately, it stenosed off and the smaller ophthalmic artery was used for the last 3 injections.Fig. 1Relapse of juxtapapillary tumor.Fig. 1Fig. 2Focal sclero-conjunctival ischaemia of the left eye.Fig. 2Fig. 3Anterior fluorescein angiography.Fig. 3

3. Discussion {#sec3}
=============

Treatment of retinoblastoma has undergone a dramatic evolution over the past three decades; from external beam radiation therapy, now known to cause increased mortality from secondary tumours in patients with germ-line mutations[@bib5]^,^[@bib6] to systemic intravenous chemotherapy (IVC) with focal laser and/or cryotherapy as standard treatment in the 1990s.[@bib7]^,^[@bib8] Intra-arterial chemotherapy, delivered directly to the globe via the internal carotid artery is now an established treatment, used as first-line treatment or second line after systemic chemotherapy[@bib3]^,^[@bib4]^,^[@bib9], [@bib10], [@bib11], [@bib12], [@bib13]

IAC, along with intravitreal chemotherapy, are now being used both to salvage more eyes as well as retain function, where previously enucleation would have been the only option. However, IAC carries the risk of significant complications. These may include systemic complications such as bradycardia, hypotension, myelosuppression or allergic reactions.[@bib3]^,^[@bib15], [@bib16], [@bib17] Local ophthalmic complications are commonly vascular in nature and include retinal or vitreous haemorrhage and retinal or choroidal vascular occlusions, including vein occlusions.[@bib12]^,^[@bib15]^,^[@bib16]^,^[@bib18], [@bib19], [@bib20], [@bib21] Rates of complications secondary to IAC are decreasing, however, as catheterisation techniques are improved[@bib19] and chemotherapy doses are adjusted to patient age.[@bib4] A median of 3 treatments has been reported in large case series[@bib12]^,^[@bib15]^,^[@bib22] and at our own centre.[@bib4] Tsimpida et al.[@bib23] found a visual loss rate of 42% for refractory retinoblastoma that was treated with IAC. However, by using age-appropriate dosing of melphalan, Reddy et al.[@bib4] demonstrated no visual loss in patients with healthy foveolae. The potential for visual loss was a major concern as this child was dependent on her only remaining eye for vision and she had a cumulative dose of 47.5 mg of melphalan. Francis et al. determined that a reduction in ERG became statistically significant at a cutoff cumulative dose of 14mg of melphalan, suggesting cumulative doses can have a deleterious effect on the retina. By multivariate analysis, however, they found that neither topotecan nor carboplatin had an effect on the ERG.[@bib23] There have been few studies on the complications of topotecan and carboplatin. It has been shown that like melphalan, these drugs are toxic to the RPE.[@bib24] Gobin et al. have shown that 50mg carboplatin can cause massive edema of the peri-ocular structures and possible myositis.[@bib3] Our patient had 3 doses of 30mg carboplatin. Daniels et al. have used animal model evidence to show that the doses of melphalan and carboplatin are the most important factors related to complications not catheterisation technique[@bib25]: indeed this corroborates Reddy et al.\'s findings.[@bib4] As topotecan has rarely been given without agents such as melphalan or carboplatin, it is difficult to tease out the topotecan specific complications of IAC.

We have previously reported anterior segment invasion by the tumor in eyes receiving IAC as salvage.[@bib26] Anterior segment ischaemia is an unusual complication of IAC, and, to the best of our knowledge, this case of sclero-conjunctival ischaemia secondary to IAC is unique. This is most likely due to the high number of IAC treatments (12 to date) that have been necessary to salvage this patient\'s remaining eye. It is possible that repeated doses of IAC have a summative effect on the ocular blood supply, risking anterior segment and neurologic sequelae. .

We would like to highlight that it is very unusual to administer such a large number of IAC infusions and that the rationale in this case was salvage of residual function in an only eye. Despite the significant morbidity from the treatment, this 5 year-old girl has functional vision in her remaining eye, with disease quiescence at most recent follow up (17 months since last treatment aged 6). Close observation will be continued in order to detect any future scleromalacia or anterior staphyloma and possible relapse.

4. Conclusion {#sec4}
=============

This case highlights the significant challenge of balancing the salvage of eyes and vision with the potentially significant morbidity associated with IAC.

Patient consent {#sec5}
===============

Consent to publish the case report was not obtained. This report does not contain any personal information that could lead to the identification of the patient.
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